These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28926120)

  • 1. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
    Wyles D; Poordad F; Wang S; Alric L; Felizarta F; Kwo PY; Maliakkal B; Agarwal K; Hassanein T; Weilert F; Lee SS; Kort J; Lovell SS; Liu R; Lin CW; Pilot-Matias T; Krishnan P; Mensa FJ
    Hepatology; 2018 Feb; 67(2):514-523. PubMed ID: 28926120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
    Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
    J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
    Toyoda H; Chayama K; Suzuki F; Sato K; Atarashi T; Watanabe T; Atsukawa M; Naganuma A; Notsumata K; Osaki Y; Nakamuta M; Takaguchi K; Saito S; Kato K; Pugatch D; Burroughs M; Redman R; Alves K; Pilot-Matias TJ; Oberoi RK; Fu B; Kumada H
    Hepatology; 2018 Feb; 67(2):505-513. PubMed ID: 28865152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E;
    J Hepatol; 2020 Mar; 72(3):431-440. PubMed ID: 31655134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
    Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
    J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
    Poordad F; Pol S; Asatryan A; Buti M; Shaw D; Hézode C; Felizarta F; Reindollar RW; Gordon SC; Pianko S; Fried MW; Bernstein DE; Gallant J; Lin CW; Lei Y; Ng TI; Krishnan P; Kopecky-Bromberg S; Kort J; Mensa FJ
    Hepatology; 2018 Apr; 67(4):1253-1260. PubMed ID: 29152781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
    Fontana RJ; Lens S; McPherson S; Elkhashab M; Ankoma-Sey V; Bondin M; Dos Santos AGP; Xue Z; Trinh R; Porcalla A; Zeuzem S
    Adv Ther; 2019 Dec; 36(12):3458-3470. PubMed ID: 31646465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
    Reau N; Kwo PY; Rhee S; Brown RS; Agarwal K; Angus P; Gane E; Kao JH; Mantry PS; Mutimer D; Reddy KR; Tran TT; Hu YB; Gulati A; Krishnan P; Dumas EO; Porcalla A; Shulman NS; Liu W; Samanta S; Trinh R; Forns X
    Hepatology; 2018 Oct; 68(4):1298-1307. PubMed ID: 29672891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
    Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    Chayama K; Suzuki F; Karino Y; Kawakami Y; Sato K; Atarashi T; Naganuma A; Watanabe T; Eguchi Y; Yoshiji H; Seike M; Takei Y; Kato K; Alves K; Burroughs M; Redman R; Pugatch DL; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Kumada H
    J Gastroenterol; 2018 Apr; 53(4):557-565. PubMed ID: 28948366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
    Kumada H; Watanabe T; Suzuki F; Ikeda K; Sato K; Toyoda H; Atsukawa M; Ido A; Takaki A; Enomoto N; Kato K; Alves K; Burroughs M; Redman R; Pugatch D; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Chayama K
    J Gastroenterol; 2018 Apr; 53(4):566-575. PubMed ID: 29052790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
    Foster GR; Asselah T; Kopecky-Bromberg S; Lei Y; Asatryan A; Trinh R; Zadeikis N; Mensa FJ
    PLoS One; 2019; 14(1):e0208506. PubMed ID: 30601818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
    Forns X; Lee SS; Valdes J; Lens S; Ghalib R; Aguilar H; Felizarta F; Hassanein T; Hinrichsen H; Rincon D; Morillas R; Zeuzem S; Horsmans Y; Nelson DR; Yu Y; Krishnan P; Lin CW; Kort JJ; Mensa FJ
    Lancet Infect Dis; 2017 Oct; 17(10):1062-1068. PubMed ID: 28818546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.
    Cornberg M; Ahumada A; Aghemo A; Andreoni M; Bhagat A; Butrymowicz I; Carmiel M; Chodick G; Conway B; Song Y; Gasbarrini A; Hüppe D; Plaza FJ; Lampertico P; Alonso MLM; Myles L; Persico M; Ramji A; Sarrazin C; Villa E; Weil C; Otano JIU;
    Adv Ther; 2022 Jul; 39(7):3146-3158. PubMed ID: 35543964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
    Zuckerman E; Gutierrez JA; Dylla DE; de Ledinghen V; Muir AJ; Gschwantler M; Puoti M; Caruntu F; Slim J; Nevens F; Sigal S; Cohen S; Fredrick LM; Pires Dos Santos AG; Rodrigues L; Dillon JF
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2544-2553.e6. PubMed ID: 32621971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.
    Yao BB; Fredrick LM; Schnell G; Kowdley KV; Kwo PY; Poordad F; Nguyen K; Lee SS; George C; Wong F; Gane E; Abergel A; Spearman CW; Nguyen T; Hung Le M; Pham TT; Mensa F; Asselah T
    Liver Int; 2020 Oct; 40(10):2385-2393. PubMed ID: 32445613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
    Meszaros M; Truchi R; Ouzan D; Tran A; Bourlière M; Pageaux GP
    Hepatology; 2021 Oct; 74(4):2304-2306. PubMed ID: 34008214
    [No Abstract]   [Full Text] [Related]  

  • 18. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
    Naganuma A; Chayama K; Notsumata K; Gane E; Foster GR; Wyles D; Kwo P; Crown E; Bhagat A; Mensa FJ; Otani T; Larsen L; Burroughs M; Kumada H
    J Gastroenterol; 2019 Aug; 54(8):752-761. PubMed ID: 30868245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
    Poordad F; Felizarta F; Asatryan A; Sulkowski MS; Reindollar RW; Landis CS; Gordon SC; Flamm SL; Fried MW; Bernstein DE; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
    Hepatology; 2017 Aug; 66(2):389-397. PubMed ID: 28128852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.
    Ueda Y; Kobayashi T; Ikegami T; Miuma S; Mizuno S; Akamatsu N; Takaki A; Ishigami M; Takatsuki M; Sugawara Y; Maehara Y; Uemoto S; Seno H
    J Gastroenterol; 2019 Jul; 54(7):660-666. PubMed ID: 30806783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.